All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
On 14th May 2017, during iwCLL, the fifth session took place titled “Additional Considerations for the Initial Treatment of CLL.” This session was chaired by Richard Furman (Weill Cornell) and Jae Park (Memorial Sloan Kettering Cancer Center).
Thomas J. Kipps, MD, PhD, from the University of California, San Diego, Moores Cancer Center, California, USA, gave a presentation during this session titled “Outcomes of Ibrutinib-Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia With High-Risk Prognostic Factors in an Integrated Analysis of 3 Randomized Phase 3 Studies.”
Del(17p), del(11q), and unmutated IGHV are prognostic factors for poor outcomes after chemo-immunotherapy for CLL/SLL patients. In the phase II PCYC-1102/1103 study (newly diagnosed = 31; R/R = 101), multivariate analysis identified del(17p) as an independent prognostic impact for worse PFS or OS.
Data from the RESONATE, RESONATE-2, and HELIOS trials were pooled and analyzed based on IGHV mutational status, del(11q), trisomy 12, and complex karyotype. Impact of del(17p) was not assessed for efficacy analyses as patients with this genetic abnormality were excluded from two of the three trials. PFS for comparator patients was also included to provide context. Multivariate analysis was undertaken to determine the risk/prognostic factors associated with PFS.
It was found that, after a median follow-up of 36.4 months (95% CI, 35.8–37.1), PFS at 36 months in ibrutinib-treated patients was 70% for unmutated IGHV compared to 77% for mutated IGHV.
Thomas J. Kipps concluded the talk by stating that ibrutinib-treated patients with trisomy 12 had significantly higher CR rate; however, PFS and OS were similar compared to those without trisomy 12. Unmutated IGHV, del(11q), and complex karyotype were adverse prognostic factors for PFS in comparator-treated patients, but not in those treated with ibrutinib. This integrated analysis found that patients with del(11q) had longer PFS than patients without del(11q). Lastly, results suggest that genomic risk factors associated with poor outcomes with traditional therapies have less relevance with ibrutinib treatment.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox